TNBC, which accounts for approximately 15–20% of all breast cancer cases, lacks the expression of hormone (oestrogen and progesterone) receptors and HER2 and is characterised by high malignancy, high recurrence rates and a poor prognosis [3]. Here, ERBB2 is linked to breast carcinoma.